ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 555,49
-0,71%
Dow Jones
39 183,34
0,14%
DAX
18 209,35
0,25%
Brent Oil
85,205
0,87%
Bitcoin
61 733,31
1,51%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cyclo Therapeutics Inc (CYTH)

  7. Cyclo Therapeutics Inc (CYTH) Actualités

CYTH

Cyclo Therapeutics (CYTH)

Cyclo Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CYTH
DateHeureSourceTitreSymboleSociété
25/06/202415h25Business WireCyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024NASDAQ:CYTHCyclo Therapeutics Inc
14/06/202422h01GlobeNewswire Inc.Rafael Holdings Reports Third Quarter Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
30/05/202415h00Business WireCyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1NASDAQ:CYTHCyclo Therapeutics Inc
16/05/202414h05Business WireCyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CYTHCyclo Therapeutics Inc
18/03/202414h05Business WireCyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CYTHCyclo Therapeutics Inc
14/03/202414h34Business WireCyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s DiseaseNASDAQ:CYTHCyclo Therapeutics Inc
13/03/202422h04GlobeNewswire Inc.Rafael Holdings Reports Second Quarter Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
04/03/202422h33Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CYTHCyclo Therapeutics Inc
15/02/202422h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTHCyclo Therapeutics Inc
14/02/202420h44Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CYTHCyclo Therapeutics Inc
29/01/202415h15Business WireCyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark OfficeNASDAQ:CYTHCyclo Therapeutics Inc
22/01/202412h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTHCyclo Therapeutics Inc
29/12/202303h48Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CYTHCyclo Therapeutics Inc
27/12/202322h15Business WireCyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.NASDAQ:CYTHCyclo Therapeutics Inc
18/12/202315h15Business WireCyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1NASDAQ:CYTHCyclo Therapeutics Inc
18/12/202312h02Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:CYTHCyclo Therapeutics Inc
14/12/202322h01GlobeNewswire Inc.Rafael Holdings Reports First Quarter Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
22/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYTHCyclo Therapeutics Inc
21/11/202315h15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CYTHCyclo Therapeutics Inc
21/11/202314h05Business WireCyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024NASDAQ:CYTHCyclo Therapeutics Inc
20/11/202314h50Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:CYTHCyclo Therapeutics Inc
15/11/202314h05Business WireCyclo Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
14/11/202320h41Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYTHCyclo Therapeutics Inc
07/11/202322h45Edgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:CYTHCyclo Therapeutics Inc
30/10/202321h01GlobeNewswire Inc.Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
24/10/202322h43Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CYTHCyclo Therapeutics Inc
23/10/202314h05Business WireCyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 MillionNASDAQ:CYTHCyclo Therapeutics Inc
05/10/202314h05Business WireCyclo Therapeutics to Present at 8th Annual Dawson James ConferenceNASDAQ:CYTHCyclo Therapeutics Inc
21/09/202315h35GlobeNewswire Inc.Dawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceNASDAQ:CYTHCyclo Therapeutics Inc
21/09/202314h05Business WireCyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger AgreementNASDAQ:CYTHCyclo Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CYTH

Dernières Valeurs Consultées

BIT
UC2783
Unicredit Bank
BIT
P1HYU4
BNP Paribas Issuance
NYSE
ECCB
Eagle Point Credit
EU
C871S
C871S
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés